Neurology News and Research

Latest Neurology News and Research

Aspirin may help postmenopausal women reduce risk of trans fat-related stroke

New research shows an increased risk of ischemic stroke in postmenopausal women who consume higher amounts of trans fatty acids, commonly found in baked goods, fried foods, and packaged products. Study findings now available in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association and Child Neurology Society, suggest aspirin use may moderate the stroke risk caused by a diet high in trans fats.

1 Mar 2012

Perception of epilepsy is not faring well in social media

A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.

1 Mar 2012

Aspirin may reduce risk of trans fat-related stroke in older women

Older women whose diets include a substantial amount of trans fats are more likely than their counterparts to suffer an ischemic stroke, a new study shows.

1 Mar 2012

ACTB and ACTG1 actin genes cause Baraitser-Winter syndrome

Scientists from Seattle Children's Research Institute and the University of Washington, in collaboration with the Genomic Disorders Group Nijmegen in the Netherlands, have identified two new genes that cause Baraitser-Winter syndrome, a rare brain malformation that is characterized by droopy eyelids and intellectual disabilities.

1 Mar 2012

RMC offers groundbreaking new procedure for LSS patients

More than one million people are diagnosed and treated each year in the United States for lumbar spinal stenosis (LSS), a condition that occurs from the narrowing of the spinal canal. Peter Staats, M.D., in conjunction with Riverview Medical Center, is offering LSS patients a groundbreaking new procedure, mild (minimally invasive spinal decompression) that safely and therapeutically reduces pain and improves mobility.

1 Mar 2012

Bayer receives FDA approval for lower dose formulation of ANGELIQ

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus.

29 Feb 2012

Tenfold increase in OARnet network bandwidth speeds will boost medical research

Following his State of the State announcement of a tenfold boost to OARnet's statewide network bandwidth, Governor John R. Kasich joined medical researchers from across the state on Feb. 27 in a video teleconference to discuss how the faster network speeds will help enhance innovation.

29 Feb 2012

AAN, ALS Association announce creation of Richard Olney Clinician Scientist Development Award

The American Academy of Neurology Foundation and The ALS Association are announcing the creation of the Richard Olney Clinician Scientist Development Award in ALS, named after Richard K. Olney, MD, a leading neurologist and pioneer in clinical ALS research who died late last month of ALS, also known as amyotrophic lateral sclerosis, or Lou Gehrig's disease.

29 Feb 2012

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 28 February 2012 to review the Group's results for 2011, published today.

29 Feb 2012

People with TBI show decline in financial management skills

People who experience a traumatic brain injury show a marked decline in the ability to make appropriate financial decisions in the immediate aftermath and a continued impairment on complex financial skills six months later, according to new research from the University of Alabama at Birmingham.

29 Feb 2012

Single dose of Ritalin may raise awareness of mistakes: Study

The study, by Dr Rob Hester from the Department of Psychological Sciences and colleagues at the Queensland Brain Institute, investigated how the brain monitors ongoing behavior for performance errors – specifically failures of impulse control. This study found that a single dose of methylphenidate (Ritalin) results in significantly greater activity in the brain’s error monitoring network and improved volunteers’ awareness of their mistakes.

28 Feb 2012

Low levels of omega-3 in blood ‘ups’ risk of dementia and brain aging: Study

Researchers looked at 1,575 adults who averaged 67 years old and had no signs of dementia and had not had a stroke. They were given MRI brain scans and a battery of tests to measure memory and thinking abilities; they also had blood drawn to check the level of docosahexaenoic acid (DHA) or omega-3 fatty acids in their red blood cells. Those with the lowest levels of omega-3s showed signs of accelerated aging. They had lower brain volume, indicating shrinkage comparable to two additional years of aging. Compared with those with the highest blood levels of omega-3s, they scored lower on cognitive tests measuring such things as memory, problem solving, abstract thinking and multi-tasking.

28 Feb 2012

Vanderbilt Kennedy Center, Autism Speaks create new sleep guide

The Vanderbilt Kennedy Center has created a resource with Autism Speaks to help improve sleep for children and teens affected by autism spectrum disorders. This new toolkit, titled "Sleep Strategies for Children with Autism: A Parent's Guide," offers strategies to help families whose children with autism have difficulty falling asleep and staying asleep through the night.

28 Feb 2012

Diets low in omega-3 fatty acids linked with memory problems

A diet lacking in omega-3 fatty acids, nutrients commonly found in fish, may cause your brain to age faster and lose some of its memory and thinking abilities, according to a study published in the February 28, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

28 Feb 2012

KF scientist to speak at William Paterson University, March 1

John DeLuca, PhD, vice president for research at Kessler Foundation, is the featured speaker at the grand opening of the new Science Complex at William Paterson University's College of Science and Health. Dr. DeLuca, a well known expert in cognitive function, will discuss "Neuroimaging, Brain and Behavior: New Opportunities for the Future," on March 1, 2012 12:30 to 1:05 pm in the Science East Lecture Hall.

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

Dopamine therapy can boost creativity in patients with Parkinson's

Some Parkinson's Disease patients can suddenly become creative when they take dopamine therapy, producing pictures, sculptures, novels and poetry. But their new-found interests can become so overwhelming that they ignore other aspects of their everyday life, such as daily chores and social activities, according to research published in the March issue of the European Journal of Neurology.

24 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

UM scientists discover high concentrations of BMAA in shark fins

Sharks are among the most threatened of marine species worldwide due to unsustainable overfishing. Sharks are primarily killed for their fins alone, to fuel the growing demand for shark fin soup, which is an Asia delicacy. A new study by University of Miami (UM) scientists in the journal Marine Drugs has discovered high concentrations of BMAA in shark fins, a neurotoxin linked to neurodegenerative diseases in humans including Alzheimer's and Lou Gehrig Disease.

24 Feb 2012

Impax announces FDA acceptance of NDA filing for IPX066

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for IPX066 for the treatment of idiopathic Parkinson's disease (PD) submitted to the Agency on December 21, 2011.

23 Feb 2012